USFDA classifies Jubilant Draximage Montreal facility as VAI
Noida: Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, has announced that its subsidiary Jubilant Draximage Inc. ('JDI') has received a communication from the U.S. Food and Drug Administration (USFDA) through which the regulatory agency intimated that pursuant to its audit of JDI’s Radiopharmaceutical manufacturing facility at Montreal, Canada in the month of April, 2024, it has determined the inspection classification of the facility as “Voluntary Action Indicated”.
Voluntary action indicated (VAI), means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
Medical Dialogues team had earlier reported that the USFDA had concluded the audit of the Jubilant HollisterStier General Partnership ("JHSGP")’s contract manufacturing facility located in Montreal, Canada.
Read also: USFDA issues 15 observations for Jubilant HollisterStier General Partnership Montreal facility
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.